To further confirm the effect of the 5-HT-liver-HTR2A axis on diet-indued hepatic steatosis through modification of hepatic lipogenesis genes, the HTR2A antagonist sarpogrelate was administered to HFD-fed WT and HFD-fed MC4RKO mice. This evidence concerns the gene HTR2A and fatty liver disease.